Drug intelligence / Profile preview

morphine + tetracaine

Development stage: Preclinical
Modality: Small Molecules
Administration: Topical, Intravenous

Overview

Morphine + tetracaine is a combination drug used for pain management. Morphine is an opioid agonist that acts on the central nervous system to relieve moderate to severe pain, while tetracaine (amethocaine) is a local anesthetic that provides topical analgesia. This combination has been studied for use in procedures such as central line placement in ventilated neonates, where it was found to provide superior analgesia compared to tetracaine alone.

Other names: morphine + amethocaine

Targets

DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)NaV (Voltage-gated sodium channels)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on morphine + tetracaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on morphine + tetracaine.

Explore the full profile